scholarly journals Incidence of primary graft dysfunction after lung transplantation is altered by timing of allograft implantation

Thorax ◽  
2018 ◽  
Vol 74 (4) ◽  
pp. 413-416 ◽  
Author(s):  
Peter S Cunningham ◽  
Robert Maidstone ◽  
Hannah J Durrington ◽  
Rajamayier V Venkateswaran ◽  
Marcelo Cypel ◽  
...  
Keyword(s):  
Cohort Studies ◽  
Lung Transplantation ◽  
Organ Preservation ◽  
Retrospective Cohort ◽  
Circadian Regulation ◽  
Primary Graft Dysfunction ◽  
Graft Dysfunction ◽  
Donor Lung ◽  
Retrospective Cohort Studies ◽  
Clock Protein

The importance of circadian factors in managing patients is poorly understood. We present two retrospective cohort studies showing that lungs reperfused between 4 and 8 AM have a higher incidence (OR 1.12; 95% CI 1.03 to 1.21; p=0.01) of primary graft dysfunction (PGD) in the first 72 hours after transplantation. Cooling of the donor lung, occurring during organ preservation, shifts the donor circadian clock causing desynchrony with the recipient. The clock protein REV-ERBα directly regulates PGD biomarkers explaining this circadian regulation while also allowing them to be manipulated with synthetic REV-ERB ligands.

Influence of Donor Lung Surfactant-A and -B Protein Expression on the Development of Primary Graft Dysfunction After Lung Transplantation: A Pilot Study

2017 ◽  
Vol 22 ◽  
pp. 361-369 ◽  
Author(s):  
Asmae Belhaj ◽  
Carine Boven ◽  
Laurence Dewachter ◽  
Maria Ruiz Patino ◽  
Youri Sokolow ◽  
...  
Keyword(s):  
Pilot Study ◽  
Protein Expression ◽  
Lung Transplantation ◽  
Lung Surfactant ◽  
Primary Graft Dysfunction ◽  
Graft Dysfunction ◽  
Donor Lung

scholarly journals Recent advances in lung transplantation

F1000Research ◽  
2018 ◽  
Vol 7 ◽  
pp. 1684 ◽  
Author(s):  
Keith C Meyer
Keyword(s):  
Lung Transplantation ◽  
Primary Graft Dysfunction ◽  
Graft Dysfunction ◽  
Donor Pool ◽  
Post Transplant ◽  
Antibody Mediated Rejection ◽  
The Past ◽  
End Stage ◽  
Transplant Complications

Lung transplantation can improve quality of life and prolong survival for individuals with end-stage lung disease, and many advances in the realms of both basic science and clinical research aspects of lung transplantation have emerged over the past few decades. However, many challenges must yet be overcome to increase post-transplant survival. These include successfully bridging patients to transplant, expanding the lung donor pool, inducing tolerance, and preventing a myriad of post-transplant complications that include primary graft dysfunction, forms of cellular and antibody-mediated rejection, chronic lung allograft dysfunction, and infections. The goal of this manuscript is to review salient recent and evolving advances in the field of lung transplantation.

Assessing the Feasibility of Retrospective Cohort Studies

1987 ◽  
Vol 12 (4) ◽  
pp. 419-430 ◽  
Author(s):  
Kyle Steenland ◽  
Leslie Stayner ◽  
Alice Greife
Keyword(s):  
Cohort Studies ◽  
Retrospective Cohort ◽  
Retrospective Cohort Studies

scholarly journals Integrative analysis correlates donor transcripts to recipient autoantibodies in primary graft dysfunction after lung transplantation

Immunology ◽  
2010 ◽  
Vol 132 (3) ◽  
pp. 394-400 ◽  
Author(s):  
Peter H. Hagedorn ◽  
Christopher M. Burton ◽  
Eli Sahar ◽  
Eytan Domany ◽  
Irun R. Cohen ◽  
...  
Keyword(s):  
Lung Transplantation ◽  
Integrative Analysis ◽  
Primary Graft Dysfunction ◽  
Graft Dysfunction

Management of Oral Anticoagulation Therapy After Gastrointestinal Bleeding: Whether to, When to, and How to Restart an Anticoagulation Therapy

2017 ◽  
Vol 51 (11) ◽  
pp. 1000-1007 ◽  
Author(s):  
Kazuhiko Kido ◽  
Michael J. Scalese
Keyword(s):  
Gastrointestinal Bleeding ◽  
Cohort Studies ◽  
Oral Anticoagulation ◽  
Retrospective Cohort ◽  
Oral Anticoagulants ◽  
Direct Oral Anticoagulants ◽  
Anticoagulation Therapy ◽  
Cochrane Library ◽  
Oral Anticoagulation Therapy ◽  
Retrospective Cohort Studies

Objective: To evaluate current clinical evidence for management of oral anticoagulation therapy after gastrointestinal bleeding (GIB) with an emphasis on whether to, when to, and how to resume an anticoagulation therapy. Data Sources: Relevant articles from MEDLINE, Cochrane Library, and EMBASE databases were identified from 1946 through May 20, 2017, using the keywords: gastrointestinal hemorrhage or gastrointestinal bleeding and antithrombotic therapy or anticoagulation therapy or warfarin or dabigatran or rivaroxaban or apixaban or edoxaban.Study Selection and Data Extraction: All English-language studies assessing management of oral anticoagulation therapy after GIB were evaluated. Data Synthesis: A total of 9 studies were identified. Four retrospective cohort studies showed that resuming anticoagulation therapy was associated with significantly lower rate of thromboembolism (TE) in the general population. Meta-analyses and prospective cohort studies also supported this finding. Two retrospective cohort studies indicated an increase in GIB when anticoagulation reinitiation occurred in less than 7 days without a decrease in TE. Resuming therapy between 7 and 15 days did not demonstrate a significant increase in GIB or TE. A large retrospective study showed that apixaban was associated with the significantly lowest risk of GIB compared with both rivaroxaban and dabigatran. Conclusion: Anticoagulation therapy resumption is recommended, with resumption being considered between 7 and 14 days following GIB regardless of the therapy chosen. Data for warfarin management after GIB should be applied with caution to direct oral anticoagulants (DOACs) because of the quicker onset and experimental nature of reversal agents. Apixaban may be a preferred option when restarting a DOAC therapy.

Primary graft dysfunction after lung transplantation

2012 ◽  
Vol 36 (7) ◽  
pp. 506-512
Author(s):  
V.J. Suárez López ◽  
E. Miñambres ◽  
J.C. Robles Arista ◽  
M.A. Ballesteros
Keyword(s):  
Lung Transplantation ◽  
Primary Graft Dysfunction ◽  
Graft Dysfunction
Sign in / Sign up

Export Citation Format

Share Document